Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism
Clinical & Translational Immunology · 2023-01 · 12 (5)
DOI: 10.1002/cti2.1451 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical & Translational Immunology, online erschienen am 17.05.2023. Verfasst von Olivia G Thomas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Therapeutic Immune Design, Centre for Molecular Medicine Karolinska Institute Stockholm Sweden. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The link between Epstein–Barr virus (EBV) and multiple sclerosis (MS) has puzzled researchers since it was first discovered over 40 years ago. Until that point, EBV was primarily viewed as a cancer‐causing agent, but the culmination of evidence now shows that EBV has a pivotal role in development of MS. Early MS disease is characterised by episodic neuroinflammation and focal lesions in the central nervous system (CNS) that over time develop into progressive neurodegeneration and disability. Risk of MS is vanishingly low in EBV seronegative individuals, history of infectious mononucleosis (acute symptomatic primary infection with EBV) significantly increases risk and elevated antibody titres directed against EBV antigens are well‐characterised in patients. However, the underlying mechanism – or mechanisms – responsible for this interplay remains to be fully elucidated; how does EBV‐induced immune dysregulation either trigger or drive MS in susceptible individuals? Furthermore, deep understanding of virological and immunological events during primary infection and long‐term persistence in B cells will help to answer the many questions that remain regarding MS pathogenesis. This review discusses the current evidence and mechanisms surrounding EBV and MS, which have important implications for the future of MS therapies and prevention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Therapeutic Immune Design, Centre for Molecular Medicine Karolinska Institute Stockholm Sweden.
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences University of Birmingham, Edgbaston Birmingham UK.
- School of Medical Sciences, Faculty of Medicine and Health The University of Sydney Camperdown NSW Australia.
- Charles Perkins Centre The University of Sydney Camperdown NSW Australia.
ORCID-Profile: Olivia G Thomas, Umaimainthan Palendira
Zitieren
APA
Thomas, O. G., Rickinson, A., & Palendira, U. (2023). Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism. Clinical & Translational Immunology, 12(5). https://doi.org/10.1002/cti2.1451
Vancouver
Thomas OG, Rickinson A, Palendira U. Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism. Clinical & Translational Immunology. 2023;12(5). doi:10.1002/cti2.1451
BibTeX
@article{Thomas2023,
author = {Thomas, Olivia G and Rickinson, Alan and Palendira, Umaimainthan},
title = {Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism},
journal = {Clinical & Translational Immunology},
year = {2023},
volume = {12},
number = {5},
doi = {10.1002/cti2.1451}
}
EUVIMED